|
1.
|
Huang TR, Zhang SW, Chen WQ, et al: Trends
in nasopharyngeal carcinoma mortality in China, 1973–2005. Asian
Pac J Cancer Prev. 13:2495–2502. 2012.PubMed/NCBI
|
|
2.
|
Cheng SH, Jian JJ, Tsai SY, et al:
Prognostic features and treatment outcome in locoregionally
advanced nasopharyngeal carcinoma following concurrent chemotherapy
and radiotherapy. Int J Radiat Oncol Biol Phys. 41:755–762. 1998.
View Article : Google Scholar
|
|
3.
|
Toh HC, Ha TC and Wee J: Personalised
medicine in nasopharyngeal cancer. Lancet Oncol. 13:568–569. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ayyanathan K, Kesaraju S, Dawson-Scully K
and Weissbach H: Combination of sulindac and dichloroacetate kills
cancer cells via oxidative damage. PLoS One. 7:e399492012.
View Article : Google Scholar
|
|
5.
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Jadvar H: Imaging evaluation of prostate
cancer with (18)F-fluorodeoxyglucose PET/CT: utility and
limitations. Eur J Nucl Med Mol Imaging. 40(Suppl 1): 5–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Schulze A and Harris AL: How cancer
metabolism is tuned for proliferation and vulnerable to disruption.
Nature. 491:364–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Erdem V, Selimoglu Sen H, Komek H, et al:
Prognostic factors in non-small cell lung cancer patients and
prognostic importance of PET/CT SUV max value. Tuberk Toraks.
60:207–217. 2012.(In Turkish).
|
|
9.
|
Chan WK, Kwong DL, Yeung DW, Huang B and
Khong PL: Prognostic impact of standardized uptake value of F-18
FDG PET/CT in nasopharyngeal carcinoma. Clin Nucl Med.
36:1007–1011. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Sandulache VC, Ow TJ, Pickering CR, et al:
Glucose, not glutamine, is the dominant energy source required for
proliferation and survival of head and neck squamous carcinoma
cells. Cancer. 117:2926–2938. 2011.PubMed/NCBI
|
|
11.
|
Zhou GQ, Tang LL, Mao YP, et al: Baseline
serum lactate dehydrogenase levels for patients treated with
intensity-modulated radiotherapy for nasopharyngeal carcinoma: a
predictor of poor prognosis and subsequent liver metastasis. Int J
Radiat Oncol Biol Phys. 82:e359–365. 2012. View Article : Google Scholar
|
|
12.
|
Brown JE, Cook RJ, Lipton A and Coleman
RE: Serum lactate dehydrogenase is prognostic for survival in
patients with bone metastases from breast cancer: a retrospective
analysis in bisphosphonate-treated patients. Clin Cancer Res.
18:6348–6355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Zen HG, Jame JM, Chang AY, et al:
Nasopharyngeal carcinoma with bone marrow metastasis. Am J Clin
Oncol. 14:66–70. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kim SH and Lee GM: Down-regulation of
lactate dehydrogenase-A by siRNAs for reduced lactic acid formation
of Chinese hamster ovary cells producing thrombopoietin. Appl
Microbiol Biotechnol. 74:152–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP
and Huang G: Knockdown of lactate dehydrogenase A suppresses tumor
growth and metastasis of human hepatocellular carcinoma. FEBS J.
279:3898–3910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Yao F, Zhao T, Zhong C, Zhu J and Zhao H:
LDHA is necessary for the tumorigenicity of esophageal squamous
cell carcinoma. Tumour Biol. 34:25–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Zhang Y, Zhang X, Wang X, et al:
Inhibition of LDH-A by lentivirus-mediated small interfering RNA
suppresses intestinal-type gastric cancer tumorigenicity through
the downregulation of Oct4. Cancer Lett. 321:45–54. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Xu RH, Pelicano H, Zhou Y, et al:
Inhibition of glycolysis in cancer cells: a novel strategy to
overcome drug resistance associated with mitochondrial respiratory
defect and hypoxia. Cancer Res. 65:613–621. 2005.
|
|
20.
|
Tang Z, Yuan S, Hu Y, et al:
Over-expression of GAPDH in human colorectal carcinoma as a
preferred target of 3-bromopyruvate propyl ester. J Bioenerg
Biomembr. 44:117–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lu W, Hu Y, Chen G, et al: Novel role of
NOX in supporting aerobic glycolysis in cancer cells with
mitochondrial dysfunction and as a potential target for cancer
therapy. PLoS Biol. 10:e10013262012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zeng ZL, Wu MW, Sun J, et al: Effects of
the biological clock gene Bmal1 on tumour growth and anti-cancer
drug activity. J Biochem. 148:319–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hu Y, Lu W, Chen G, et al: K-ras(G12V)
transformation leads to mitochondrial dysfunction and a metabolic
switch from oxidative phosphorylation to glycolysis. Cell Res.
22:399–412. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Chen G, Chen Z, Hu Y and Huang P:
Inhibition of mitochondrial respiration and rapid depletion of
mitochondrial glutathione by beta-phenethyl isothiocyanate:
mechanisms for anti-leukemia activity. Antioxid Redox Signal.
15:2911–2921. 2011. View Article : Google Scholar
|
|
25.
|
Zhao Y, Liu H, Liu Z, et al: Overcoming
trastuzumab resistance in breast cancer by targeting dysregulated
glucose metabolism. Cancer Res. 71:4585–4597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hammoudi N, Ahmed KB, Garcia-Prieto C and
Huang P: Metabolic alterations in cancer cells and therapeutic
implications. Chin J Cancer. 30:508–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Chen Z, Lu W, Garcia-Prieto C and Huang P:
The Warburg effect and its cancer therapeutic implications. J
Bioenerg Biomembr. 39:267–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Fanciulli M, Bruno T, Giovannelli A, et
al: Energy metabolism of human LoVo colon carcinoma cells:
correlation to drug resistance and influence of lonidamine. Clin
Cancer Res. 6:1590–1597. 2000.
|
|
29.
|
Sun W, Liu Y, Glazer CA, et al: TKTL1 is
activated by promoter hypomethylation and contributes to head and
neck squamous cell carcinoma carcinogenesis through increased
aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res.
16:857–866. 2010. View Article : Google Scholar
|
|
30.
|
Seo M, Kim JD, Neau D, Sehgal I and Lee
YH: Structure-based development of small molecule PFKFB3
inhibitors: a framework for potential cancer therapeutic agents
targeting the Warburg effect. PLoS One. 6:e241792011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Elwood JC: Effect of oxamate on glycolysis
and respiration in sarcoma 37 ascites cells. Cancer Res.
28:2056–2060. 1968.PubMed/NCBI
|
|
32.
|
Liu H, Savaraj N, Priebe W and Lampidis
TJ: Hypoxia increases tumor cell sensitivity to glycolytic
inhibitors: a strategy for solid tumor therapy (Model C). Biochem
Pharmacol. 64:1745–1751. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Zhou M, Zhao Y, Ding Y, et al: Warburg
effect in chemosensitivity: targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Zhao YH, Zhou M, Liu H, et al:
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock
factor 1 promotes breast cancer cell glycolysis and growth.
Oncogene. 28:3689–3701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Liu H, Hu YP, Savaraj N, Priebe W and
Lampidis TJ: Hyper-sensitization of tumor cells to glycolytic
inhibitors. Biochemistry. 40:5542–5547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Aghaee F, Pirayesh Islamian J and
Baradaran B: Enhanced radiosensitivity and chemosensitivity of
breast cancer cells by 2-deoxy-d-glucose in combination therapy. J
Breast Cancer. 15:141–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Manerba M, Vettraino M, Fiume L, et al:
Galloflavin (CAS 568-80-9): a novel inhibitor of lactate
dehydrogenase. Chem Med Chem. 7:311–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Cheng G, Zielonka J, Dranka BP, et al:
Mitochondria-targeted drugs synergize with 2-deoxyglucose to
trigger breast cancer cell death. Cancer Res. 72:2634–2644. 2012.
View Article : Google Scholar : PubMed/NCBI
|
